Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THB001 in adults with chronic cold urticaria
NL-OMON51543Phase 1Active, not recruiting
- Sponsor
- Third Harmonic Bio
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of THB001 in Cold urticaria (CU) (3 arms), sponsored by Third Harmonic Bio. Primary endpoints: Treatment-emergent adverse events and serious adverse events, Laboratory assessments and 1 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
THB001
03
Conditions
Cold urticaria (CU)
Beyond the preview
Go deeper on NL-OMON51543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51543.